[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346591-105":59,"doc-detail-346591-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","fragmentomic-liquid-biopsy-enables-early-breast-cancer-detection-molecular-subtyping-and-lymph-node-assessment","Fragmentomic liquid biopsy enables early breast cancer detection - molecular subtyping and lymph node assessment","","Fragmentomic liquid biopsy improves early breast cancer detection and downstream characterization through cfDNA fragmentomic features. A multicenter case-control study develops TuFEst, a machine learning model trained on genome-wide cell-free DNA fragment patterns, achieving high sensitivity (95%) and specificity (78.3%) while detecting malignancies missed by conventional imaging. The framework extends to non-invasive molecular subtyping (TuFEst-MS) and lymph node status prediction (TuFEst-LN), with strong validation in independent cohorts, including imaging-pathology discordant cases. Tumor transcriptomic profiling links higher TuFEst cancer scores to aggressiveness and immune-related programs, supporting clinical utility for integrated detection, subtyping, and lymph node evaluation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fragmentomic-liquid-biopsy-enables-early-breast-cancer-detection-molecular-subtyping-and-lymph-node-assessment/346591/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fragmentomic-liquid-biopsy-enables-early-breast-cancer-detection-molecular-subtyping-and-lymph-node-assessment/346591.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is TuFEst and what clinical performance does it achieve?","Question",{"text":113,"@type":114},"TuFEst is a machine learning model built from genome-wide cfDNA fragmentomic features. It achieves 95% sensitivity and 78.3% specificity for early cancer detection and can identify malignancies missed by conventional imaging.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the approach support molecular subtyping and lymph node assessment?",{"text":118,"@type":114},"The framework is extended into TuFEst-MS for non-invasive molecular subtyping and TuFEst-LN for lymph node status prediction. It shows strong performance in independent validation cohorts, including cases where imaging and pathology disagree.",{"name":120,"@type":111,"acceptedAnswer":121},"Why are fragmentomic cfDNA analyses considered suitable for population screening?",{"text":122,"@type":114},"Fragmentomic methods require minimal blood volume (≤5 mL) and support high-throughput processing. They preserve tissue-specific signatures and avoid practical limitations seen in mutation- and methylation-based liquid biopsy approaches for early-stage disease.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346591,1790153433,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Article [https://doi.org/10.1038/s41467-026-70204-w](https://doi.org/10.1038/s41467-026-70204-w)  \nFragmentomic liquid biopsy enables early breast cancer detection, molecular subtyping and lymph node assessment  \nReceived: 24 June 2025  \n\n| Accepted: 17 February 2026 |\n| --- |\n| |\n| Check for updates |\n\nYuxuan Zhu1,2,3,14, Siwei Zheng 1,2,3,14, Yinkuan Shao 1,14, Jun Zhou2,3,4,14, Xidong Gu5,14, Lesang Shen1,2,3,14, Xue Li 6, Wenjia Liu7, Wei Xue7, Haiqi Lu8, Jun Zhou9, Jinghua Ding10, Haiming Deng11, Jiayin Chen5, Zhuohang Yu2,3, Yao Yao1,2,3, Wenjie Xia12, Wuzhen Chen1,2,3, Shanshan Sun1,2,3, Zheng Wang1,2,3, Tianyi Qian1,2,3, Xiuyan Yu1,2,3, Jian Liu4, Yiding Chen 1 , Ziao Lin 13 , Jian Huang 1,2,3  & Chao Ni 1,2,3   \nBreast cancer remains a leading global health concern in women, while screening is still limited by imaging accessibility and reduced sensitivity in dense breasts. Here we conduct a multicenter case-control study including503 breast cancer patients and 289 benign controls to develop TuFEst, a machine learning model based on genome-wide cell-free DNA fragmentomic features. TuFEst achieves high sensitivity (95%) and speciﬁcity (78.3%) for early cancer detection and reliably identiﬁes malignancies missed by conventional imaging. Extension of this framework enables non-invasive molecular subtyping (TuFEst-MS) and lymph node status prediction (TuFEst-LN), with strong performance in independent validation cohorts and imaging-pathology discordant cases. Transcriptomic proﬁling of paired bulk tumor samples (n =79) demonstrates that elevated TuFEst-derived cancer scores reﬂect tumor aggressiveness and immune-related biological programs. Together, these ﬁndings support cfDNA fragmentomics as an integrated liquid biopsy strategy for breast cancer management, enabling concurrent detection, molecular subtyping, and lymph node evaluation with potential clinical utility.  \nBreast cancer (BC) is the most common malignancy and a leading cause of cancer-related mortality in women worldwide, accounting for approximately 30% of female cancers and 15% of cancer deaths1. In China, its incidence has surged, with new cases rising from 3 million in 2015 to 4.2 million in 2020, now ranking as the fourth most prevalent cancer overall2.  \nEarly detection is critical to reduce mortality. The U.S. Preventive Services Task Force strongly endorses population-level BC screening because of its proven survival beneﬁts3. However, global screening practices vary widely. In the U.S., annual or biennial mammography is standard for women aged 40-74, with intervals tailored to individual risks3. In contrast, China’s “Two Cancers” program (BC and cervical  \ncancer) recommends triennial to quinquennial screenings, contingent on local resources. During 2018–2019, only 22.3% of eligible Chinese women underwent BC screening4. This limited coverage stems from both structural and clinical factors. On the infrastructure side, many primary-level hospitals lack mammography equipment, which creates signiﬁcant access barriers. On the clinical side, while national guidelines favor ultrasound over mammography for better detection of typically dense breast tissue in Asian women4, this preference comes with operational challenges. Diagnostic inconsistencies lead not only to missed cancers (higher interval rates) but also to overtreatment, straining healthcare insurance funds. These disparities directly impact diagnosis timing: 24.1% of Chinese BC patients are diagnosed at Stage  \nA full list of afﬁliations appears at the end of the paper. e-mail: [ydchen@zju.edu.cn](ydchen@zju.edu.cn); [ziaolin@zju.edu.cn](ziaolin@zju.edu.cn); [hjys@zju.edu.cn](hjys@zju.edu.cn); [drnichao@zju.edu.cn](drnichao@zju.edu.cn)  \nIII+ versus 11.8% in the U.S., which signiﬁcantly impairs the prognosis and increases treatment costs2.  \nThese challenges underscore the urgent need for standardized operator-independent screening solutions. Liquid biopsy approaches, particularly cell-free DNA (c","cbCaigFdUtMHZF1P","https://ap.wps.com/l/cbCaigFdUtMHZF1P","pdf",3280001,16,"English","# Study aim and clinical need\n## Study design and TuFEst development\n## Extensions: TuFEst-MS and TuFEst-LN\n## Biological validation via transcriptomics\n## Background on screening limitations and access barriers\n## Advantages and limitations of existing liquid biopsy approaches","[{\"question\":\"What is TuFEst and what clinical performance does it achieve?\",\"answer\":\"TuFEst is a machine learning model built from genome-wide cfDNA fragmentomic features. It achieves 95% sensitivity and 78.3% specificity for early cancer detection and can identify malignancies missed by conventional imaging.\"},{\"question\":\"How does the approach support molecular subtyping and lymph node assessment?\",\"answer\":\"The framework is extended into TuFEst-MS for non-invasive molecular subtyping and TuFEst-LN for lymph node status prediction. It shows strong performance in independent validation cohorts, including cases where imaging and pathology disagree.\"},{\"question\":\"Why are fragmentomic cfDNA analyses considered suitable for population screening?\",\"answer\":\"Fragmentomic methods require minimal blood volume (≤5 mL) and support high-throughput processing. They preserve tissue-specific signatures and avoid practical limitations seen in mutation- and methylation-based liquid biopsy approaches for early-stage disease.\"}]","Fragmentomic liquid biopsy enables early breast cancer detection - molecular subtyping and lymph node assessment | PDF",1790062065,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4a98d789353f235242f881c17657f4e.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8562385da975d4ea55aa0b2ff9c3ab14.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9f36dcdca06b7e496e3a35bcc698a63.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4922a16dcd66005b32c49948938d882.webp",980,1301]